Skip to content
Home/Companies/Biotech/Numab Therapeutics

Numab Therapeutics

Biotech·Switzerland·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns Numab Therapeutics?

Numab Therapeutics is a Swiss Biotech company, currently owned by Novo Holdings since 2021.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Novo Holdings
Investor
Novo Holdings
Novo Holdings Growth Investments · 1999 · Growth

Key facts

HQSwitzerland
SectorBiotech
StatusActive

More from Novo Holdings Growth Investments

Other portfolio companies in the same fund.

Surya Hospitals
Active
HealthcareIndia· 2026
Phasecraft
Phasecraft
Active
Deep TechUK· 2025
AvenCell
Active
BiotechUS· 2024
Cleveland Diagnostics
Active
MedTechUS· 2024
Convergent
Active
BiotechUS· 2024
Medi Assist
Active
HealthTechIndia· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Numab Therapeutics?

Numab Therapeutics is currently owned by Novo Holdings, through Novo Holdings Growth Investments, since 2021.

When did Novo Holdings acquire Numab Therapeutics?

Novo Holdings acquired Numab Therapeutics in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue